Clinical Trial

A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM) following 16 weeks of treatment.
Protocol Amendment History 1 change
critical Trial completed 2026-06-19
Trial Details
NCT Number NCT06982846
Lead Sponsor Eli Lilly and Company
Conditions Type 2 Diabetes Mellitus
Enrollment 80 participants
Start Date 2025-06-06
Primary Completion 2026-05-04 (estimated)
Study Completion 2026-05-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-18